Loading
Surgeon who led the CROSS trial, which made chemoradiotherapy before surgery the standard for oesophageal cancer.
Jan van Lanschot led the Dutch CROSS trial showing neoadjuvant carboplatin, paclitaxel and radiotherapy followed by surgery nearly doubles median survival compared with surgery alone in oesophageal and junctional cancer, a regimen adopted worldwide. He then led the SANO trial of active surveillance after complete clinical response, opening organ preservation in oesophageal cancer.
Shares SANO, CROSS, Paclitaxel / nab-paclitaxel, Oesophageal cancer.
Shares SANO, CROSS, Oesophageal cancer.
Shares SANO, CROSS, Oesophageal cancer.
Shares Paclitaxel / nab-paclitaxel, Carboplatin and the tag chemoradiotherapy.
Shares CROSS, Oesophageal cancer.
Shares Oesophageal cancer and the tag surgery.
Shares Oesophageal cancer and the tag esophageal.
Shares Oesophageal cancer and the tag surgery.